322 related articles for article (PubMed ID: 27249719)
1. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
Vaishampayan UN
Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
3. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
4. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
[TBL] [Abstract][Full Text] [Related]
5. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
11. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
Pantuck AJ; Belldegrun AS; Figlin RA
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
14. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Conti SL; Thomas IC; Hagedorn JC; Chung BI; Chertow GM; Wagner TH; Brooks JD; Srinivas S; Leppert JT
Int J Cancer; 2014 May; 134(9):2245-52. PubMed ID: 24135850
[TBL] [Abstract][Full Text] [Related]
15. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive nephrectomy: past, present and future.
Galazi M; Rodriguez-Vida A; Josephides E; Chau NM; Chowdhury S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):271-7. PubMed ID: 24392671
[TBL] [Abstract][Full Text] [Related]
17. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
[TBL] [Abstract][Full Text] [Related]
18. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
Wiecek W; Karcher H
PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
[TBL] [Abstract][Full Text] [Related]
20. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]